The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 2.93 — safe zoneOK
- Earnings-manipulation signal · Beneish M -3.12 — no flag raisedOK
- Earnings quality 78/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as IMMUCELL CORP /DE/ reports it. History and quarterly detail are in the app.
- Corporate Segment, Scours$27.4M
- Corporate Segment, Mastitis$196K
Leadership changes
From IMMUCELL CORP /DE/'s own filings, the day they're filed.
- Bobbi Jo Brockmann · Director · departureeff. 2026-04-15
- Michael F. Brigham · Director · departureeff. 2026-04-15
- Syracuse University · appointmenteff. 2026-04-01
Latest filings
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-07-09
- 8-K · Company announcement2026-06-17
- 8-K · Company announcement2026-06-10
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about IMMUCELL CORP /DE/, every answer cited to the official filings🔒
- The Intelligence Brief — added when IMMUCELL CORP /DE/'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.